Clinical Trial Detail

NCT ID NCT03122548
Title Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Aduro Biotech, Inc.
Indications

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

CRS-207 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.